Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;9(2):e00726.
doi: 10.1002/prp2.726.

Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection

Affiliations
Review

Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection

Henriikka Hakomäki et al. Pharmacol Res Perspect. 2021 Apr.

Abstract

Buprenorphine is a semi-synthetic opioid, widely used in the maintenance treatment for opioid-dependent pregnant women. Limited data exist on the pharmacokinetics of buprenorphine in pregnancy. We conducted a pharmacokinetic study to determine the pharmacokinetics of intravenous buprenorphine in pregnant sheep. Fourteen pregnant sheep in late gestation received 10 µg/kg of buprenorphine as an intravenous bolus injection. Plasma samples were collected up to 48 h after administration. Buprenorphine and its metabolite, norbuprenorphine, were quantified from plasma using a LC/MS/MS method, with lower limits of quantification of 0.01 µg/L and 0.04 µg/L for buprenorphine and norbuprenorphine, respectively. The pharmacokinetic parameters were calculated using noncompartmental analysis. The pharmacokinetic parameters, median (minimum-maximum), were Cmax 4.31 µg/L (1.93-15.5), AUCinf 2.89 h*µg/L (1.72-40.2), CL 3.39 L/h/kg (0.25-6.02), terminal t½ 1.75 h (1.07-31.0), Vss 8.04 L/kg (1.05-49.3). Norbuprenorphine was undetected in all plasma samples. The median clearance in pregnant sheep was higher than previously reported for nonpregnant sheep and human (male) subjects. Our sensitive analytical method was able to detect long terminal half-lives for six subjects, and a wide between-subject variability in the study population. Significance statement: Buprenorphine is widely used for the treatment of opioid use disorder in pregnancy. However, limited data exist on the pharmacokinetics of buprenorphine during pregnancy. As this type of study cannot be done in humans due to ethical reasons, we conducted a study in pregnant sheep. This study provides pharmacokinetic data on buprenorphine in pregnant sheep and helps us to understand the pharmacokinetics of the drug in humans.

Keywords: buprenorphine; pharmacokinetics; pregnancy; sheep.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Individual buprenorphine plasma concentrations from (A) eight pregnant sheep that showed quantifiable plasma concentrations up to 7 h after administration and (B) six pregnant sheep that showed quantifiable plasma concentrations up to 48 h after intravenous injection of 10 µg/kg buprenorphine (sheep ID 7 in orange). LLOQ 0.01 µg/L. Concentrations are shown on a semi‐logarithmic scale and are expressed as buprenorphine‐free base

Similar articles

Cited by

References

    1. Huang P, Kehner GB, Cowan A, Liu‐Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001;297(2):688‐695. - PubMed
    1. Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, Brandt MR. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol. 2002;13:557‐570. 10.1097/00008877-200211000-00005 - DOI - PubMed
    1. Bloms‐Funke P, Gillen C, Schuettler AJ, Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides. 2000;21(7):1141‐1146. 10.1016/S0196-9781(00)00252-7 - DOI - PubMed
    1. Virk MS, Arttamangkul S, Birdsong WT, Williams JT. Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009;29(22):7341‐7348. 10.1523/JNEUROSCI.3723-08.2009 - DOI - PMC - PubMed
    1. Clarke’s Analysis of Drugs and Poisons: Buprenorphine. https://www.medicinescomplete.com/#/content/clarke/c‐d1e168521?hspl=bupr.... Published 2019. Accessed March 10, 2020.

Publication types

MeSH terms